What are the clinical features of Ramsay Hunt syndrome and how can it be excluded?

Clinical Features of Ramsay Hunt Syndrome

Ramsay Hunt syndrome is diagnosed by the classic triad of peripheral facial nerve palsy, vesicular rash on the ear or in the mouth, and ear pain—but you must recognize that up to 14% of patients develop vesicles AFTER facial weakness begins, meaning early cases may be clinically indistinguishable from Bell's palsy 1.

Core Clinical Features

The defining characteristics include:

• Ipsilateral peripheral facial paralysis (complete unilateral facial weakness affecting both upper and lower face)
• Vesicular rash in the geniculate zone: ear canal, pinna, or oral mucosa (herpes zoster oticus)
• Severe ear pain (often preceding other symptoms)

Extended Neurological Involvement

Cranial nerve involvement beyond CN VII occurs in up to 50% of cases and indicates more extensive disease with poorer prognosis 2. Look for:

• CN VIII (vestibulocochlear) - most common due to anatomical proximity 2, 1:

  • Hearing loss (sensorineural)
  • Tinnitus
  • Vertigo, nausea, vomiting
  • Nystagmus

• Other cranial nerves (CN V, IX, X, XI, XII) - less common but possible 2, 3

• Autonomic dysfunction:

  • Altered taste
  • Decreased lacrimal secretion
  • Decreased nasal secretion 4

Atypical Skin Patterns

Variable skin involvement patterns occur due to individual anastomoses between cranial and cervical nerves, potentially extending to C2-C3 dermatomes 4, 5. This can complicate recognition and may be confused with contact dermatitis or simple HSV outbreaks 6.

How to Exclude Ramsay Hunt Syndrome

Clinical Exclusion Strategy

The critical challenge is that Ramsay Hunt syndrome may initially present identically to Bell's palsy before vesicles appear 1. Therefore:

1. Timing is crucial: If facial palsy exists WITHOUT vesicles, you cannot definitively exclude RHS in the first 14 days, as vesicles may develop later 1

2. Look for distinguishing features that favor RHS over Bell's palsy:

   • More severe paralysis at onset 1
   • Presence of severe ear pain (less common in Bell's palsy)
   • Any vestibulocochlear symptoms (hearing loss, vertigo, tinnitus) 1
   • Any visible vesicular rash in auricular region or oral mucosa

3. Consider "zoster sine herpete": Some patients have VZV-related facial paralysis without ever developing visible rash, detectable only by fourfold rise in VZV antibody or VZV DNA in auricular skin, blood, middle ear fluid, or saliva 1

Laboratory/Imaging Exclusion

• Serologic testing: Fourfold rise in VZV antibody titers
• PCR testing: VZV DNA in auricular skin, blood mononuclear cells, middle ear fluid, or saliva 1
• Audiometry: To document sensorineural hearing loss if CN VIII involved
• MRI: May be needed to exclude other causes of facial palsy or assess for complications like encephalitis 7

Critical Pitfall

Do not wait for vesicles to appear before treating suspected RHS 1, 8. Given that:

• 14% develop vesicles after facial weakness onset
• Early treatment (within 7 days) significantly improves outcomes
• Bell's palsy is also associated with HSV and benefits from antiviral therapy

The practical approach is to treat all acute peripheral facial palsies with combination antiviral (acyclovir 800mg five times daily or famciclovir 500mg three times daily) plus corticosteroids (prednisone 60mg daily for 3-5 days) for 7-10 days, regardless of whether vesicles are present 1, 8. This covers both RHS and HSV-associated Bell's palsy.

Poor Prognostic Indicators

• Advanced age 2
• Immunocompromised status 2
• Delayed initiation of antiviral and corticosteroid therapy 2, 4
• Polycranial nerve involvement 2
• More severe initial paralysis 1